Kornimate/medical-research-clean huggingface dataset:
effects of cannabidiol in patients: evaluation

Conditions: Substance-Related Disorders

Summary: since its recent marketizing in france, the cannabidiol (cbd), a major component of cannabis, is used in many over-the-counter products in france. some painful patients or patients suffering from addiction seem to use the cbd in search of therapeutic effects. yet, there are no data available for patients in algology and addictology, particularly with regard to the prevalence of the use of cbd, the effects sought and felt. faced with the emergence of the use of a substance with a therapeutic purpose but outside a medical framework and without monitoring of adverse effects, it becomes essential to characterize the use of cbd. the main objective of the study is therefore to assess the prevalence of cbd users in algology and addictology departments. secondary objectives are to characterize the use of cbd as well as the users of cbd, and to evaluate the impact of the use of cbd on other psychoactive substances use or current drug treatments and the drug liking of cbd.

physicians from algology and addictology departments will propose the study to all patients who meet the inclusion criteria during a medical consultation (in hospitalization or ambulatory care). if the patient agrees to participate, the non-opposition will be collected and the physician will complete a short form with sociodemographic data, medical history and contact details of the patient. the form will be transmitted securely to the research staff that will perform a unique research evaluation face to face (when the patient is still hospitalized and available) or by phone (when the patient is not available during hospitalization or no longer hospitalized or in case of ambulatory care). the research evaluation includes data about the frequency and the duration of the use of all substances (cbd included) in the last 12 months and the frequency of current drug treatments. for patients with cbd use in the last 12 months, additional data regarding the use of cbd will be collected: the form, the route of administration, the effects sought and felt, the method of obtaining, the impact on other drugs and/or substances use and the drug liking of cbd. a descriptive analysis will be carried out. the cbd user group and the cbd non-user group will be compared on all the variables collected. a multivariate analysis will be carried out in order to identify factors associated to cbd use in algology and addictology patients.

Eligibility criteria:
inclusion criteria: * minimum age of 18 years * patients for whom hospital specialists in algology or addictology have been requested (for hospitalized or ambulatory cares) during the inclusion period. * giving oral non opposition to participate. exclusion criteria: * adults under guardianship or curator * patients unable to respond to the research evaluation (cerebral function disorder, difficulty to understand, read or write french language).

Keywords: cannabidiol prevalence epidemiology pain substance-related disorders
comparison of standard opioid prescription versus prescription guided by pharmacogenetic analysis in patients with non-cancerous chronic pain.

Conditions: Non-cancerous Chronic Pain

Summary: the investigators hypothesize that opioid prescription guided by patient pharmacogenetic profile will diminish opioid-associated undesirable effects by 50% and improve medication compliance.


Eligibility criteria:
inclusion criteria: * the patient must have given their free and informed consent and signed the consent form * the patient must be a member or beneficiary of a health insurance plan * the patient is at least 18 years old * the patient will be available for all visits * patients suffer from non-cancerous chronic pain according to has criteria * patient not having taking opioids in previous 2 months * patient indicated for prescription of opioids (oxycodone, codeine or tramadol) or patient not responding to first line treatment exclusion criteria: * the subject is participating in an category i interventional study, or is in a period of exclusion determined by a previous study * the subject refuses to sign the consent * it is impossible to give the subject informed information * the patient is under safeguard of justice or state guardianship * the patient is pregnant or breastfeeding * the patient is likely to procreate and does not use an effective method of contraception (contraceptive ring, surgical contraception, implant, patch, contraceptive pill, male and female condoms, iud) * there is a contra-indication for opioid use * patient with an addiction risk (score ≥ 8 on ort scale).
an efficacy and safety study of tanezumab for the treatment of pain associated with chronic abacterial prostatitis

Conditions: Chronic Prostatitis With Chronic Pelvic Pain Syndrome

Summary: the purpose of this study is to determine whether tanezumab is effective in the treatment of pain associated with chronic prostatitis.


Eligibility criteria:
inclusion criteria: * diagnosis of chronic prostatitis * male adults at least 18 years of age * moderate to severe chronic prostatitis, with an average pain score above a pre-defined level * to use contraception. exclusion criteria: * history of symptoms for less than 3 of the last 6 months * history of recurrent urinary tract infections, or genito-urinary cancer * use of finasteride or dutasteride within 6 months. * history of hepatitis b, c or human immunodeficiency virus (hiv)

Keywords: chronic prostatis
imputation of arterial oxygen partial pressures using pulse oximetry

Conditions: Oxygen Saturation; Respiratory Distress Syndrome; Anesthesia, General

Summary: this study aims to validate existing pao₂ prediction equations (rice, pandharipande, gadrey, hill, severinghaus-ellis) by comparing predicted pao₂ values with measured values. if these equations are found to be invalid, new pao₂ prediction formulas will be derived and validated for accuracy and performance. the included blood samples are arterial blood sample collected for abgs analysis through either an arterial catheter or an arterial blood puncture in adult patients (age \>18 years) undergoing general anesthesia regardless of the acuity of the surgery (elective, emergency, or lifesaving), the hemodynamic stability of the patient, or the comorbidities. patients undergoing cardiac or thoracic surgeries will be excluded.

the partial pressure of oxygen in the arterial blood (pao2) / the fraction of inspired oxygen (fio2) ratio has been commonly used as an indicator of adequate oxygenation and in the diagnosis and severity of acute respiratory distress syndrome (ards) which requires arterial blood gas (abgs) analysis. another way to measure oxygenation is by using the noninvasive pulse oximetry to measure the oxygen saturation (spo2). three formulas have been derived and validated in the intensive care unit (icu) setting to estimate the pao2 from the spo2. however, the relationship of pao2 and spo2 and these derivation equations are not validated in the setting of general anesthesia in the operating theatre (ot) in which patients are prone to multiple intraoperative and postoperative pulmonary complications. the aim is to validate existing pao₂ prediction equations (rice, pandharipande, gadrey, hill, severinghaus-ellis) by comparing predicted pao₂ values with measured values. if these equations are found to be invalid, new pao₂ prediction formulas will be derived and validated for accuracy and performance. this is a prospective cohort study that will be conducted at the american university of beirut medical center (aubmc) in the ot under the department of anesthesiology and pain medicine. the data will be collected by the investigators of the study. these include the pao2 (in mmhg), fio2, spo2 (in %), and mean airway pressure (in cmh2o) at the time of sample collection, in addition to patient characteristics as age, gender, weight, height, bmi, smoking status, surgery type, surgery acuity, and present comorbidities specifically cardiac and respiratory comorbidities. validating the use of one of the formulas to derive pao2 from spo2 in the ot would help anesthesiologists detect derangements in patients' oxygenation earlier and decrease the need for abgs analysis and its possible complications.

Eligibility criteria:
inclusion criteria: * age \>18 years * undergoing general anesthesia exclusion criteria: * patients undergoing cardiac or thoracic surgeries will be excluded.
effects of body structures and function on actıvıty and partıcıpatıon in patıents wıth carpal tunnel syndrome

Conditions: Carpal Tunnel Syndrome

Summary: the aim of our study is to determine pain, sensation and electrodiagnostic findings in cts; to examine its effects on activity and participation.

50 patients aged 20-55 years diagnosed with mild and moderate carpal tunnel syndrome according to aanem will be included. vas, lanss, boston carpal tunnel questionnaire (symptom severity scale - functional status scale), q-dash, hand grip sensitivity measurement, hand pressure sensitivity measurement will be applied to the participants. in order to examine the relationship between body structure and functions (pain, sensation, emg findings) and activity and participation with the amos program, the maximum likelihood method will be selected and a structural equation model (sem) will be established.

Eligibility criteria:
inclusion criteria: * being diagnosed with mild-moderate cts * being between the ages of 20-55 * volunteering to participate in the study exclusion criteria: * being diagnosed with severe cts * have systemic inflammatory disease * having a disease that can cause polyneuropathy, such as diabetes mellitus * being receiving psychotherapy * illiteracy * have a hearing problem * have cognitive impairment * having a pacemaker

Keywords: pain proprioception sensation emg icf
statin lowering testosterone and sexual function

Conditions: Sexual Dysfunction

Summary: statins may decrease serum testosterone levels via decreasing cholesterol. this longitudinal study detected the effects of rosuvastatin on free testosterone levels and sexual function in men with type 2 diabetes. methods: investigator enroll 150 men with type 2 diabetes and hypercholesterolemia. biochemical assessments include serum total cholesterol (tc), low-density lipoprotein (ldl), high-density lipoprotein, triglyceride, prolactin, thyroid-stimulating hormone, luteinizing hormone, follicle stimulating hormone, total testosterone and serum sex hormone binding globulin (shbg). all parameters are measured before statin treatment, after 6 months of statin treatment and 6 months after discontinuing statin treatment. scores of the sexual health inventory for men (shim) are also evaluated.

autonomic neuropathy and hypogonadism are the cause of impotence in men with diabetes. hypercholesterolemia is also one of the dominant co-morbidity of diabetes. many men with diabetes are being treated with statins to low down the serum levels of cholesterol. however, cholesterol is the major substrate for testosterone biosynthesis, statin may decrease serum testosterone levels via decreasing cholesterol level. in previous studies, few longitudinal studies with few enrolled subject were done before and with conflict results. free testosterone is also not routinely used, so compromised the accuracy. the investigators will analyze the effect of statins on free testosterone levels in a longitudinal study of men with type 2 diabetes and do animal study to realize if the statin will influence the sex organ of rat. methods: investigator will enroll 150 men with type 2 diabetes and hypercholesterolemia. clinical and biochemical assessments include blood pressure, hba1c, lipid profile, height, weight, and waist circumference, luteinizing hormone (lh), follicle stimulating hormone (fsh) and free testosterone , which will be measured before statin treatment, after 3 months of statin treatment and then after quitted statin treatment for 3 months, and also give questionnaire about sex function. the investigators expect: 1. statin may potentially lead to hypogonadism or impotence in men with type 2 diabetes. 2. the relationship between blood glucose, lipid profile, blood pressure, anthropometric measures and serum free testosterone levels may also be revealed. 3. if this hypothesis is adverse, statin treatment will not influence gonadal function and has that side effect.

Eligibility criteria:
inclusion criteria: 1. type2 diabetes mellitus for more than 2 year. 2. male subjects 3. not received statin therapy for more than 1 year 4. normal sexual activity 5. no hypogonadism history. exclusion criteria: 1. type 1 diabetes mellitus 2. duration of diabetes less than 2 years and more than 10 years 3. renal function impairment (creatinine level \> 1.4 mg/dl) 4. cancer or organic disease associated with hypogonadism, 5. with testosterone on antiandrogen drug therapy

Keywords: diabetes hypercholesterolemia sexual dysfunction statin testosterone
response of patients on surveillance for prostate cancer to dutasteride

Conditions: Prostate Cancer

Summary: hypothesis: that, in men on surveillance for favorable risk prostate cancer treated with dutasteride, prostate specific antigen (psa) kinetics is of value in identifying those men who harbor occult high grade prostate cancer. the study will determine the prevalence of a secondary rise in psa \> 0.5 ng/ml and the psa doubling time in subjects on surveillance being treated with dutasteride.

this analysis is a subset of the data associated with the active surveillance cohort at sunnybrook health sciences centre. approximately 150 subjects within the cohort have received dutasteride therapy from 6 months to 3 years. all subjects have had serial psas at regular intervals between 3 to 6 months, and all have had a biopsy performed within 1 to 3 years of initiating dutasteride. the prevalence of a secondary rise in psa \> 0.5ng/ml will be calculated with the impact of dutasteride therapy on the psa doubling time. this information will be correlated with baseline psa value, prostate volume, extent of disease on initial biopsy and baseline psa kinetics. psa kinetics will be also correlated with gleason score upgrading on repeat biopsy. the rate of negative biopsies in men on dutasteride therapy will be compared with a similar group of surveillance subjects not treated with dutasteride.

Eligibility criteria:
inclusion criteria: * patients on active surveillance for favorable risk prostate cancer who have been treated with dutasteride following the diagnosis of cancer.

Keywords: prostate cancer psa kinetics psa doubling time active surveillance
observational trial of the impact of radiation dose in children with brain and skull base tumors.

Conditions: Brain Tumor; Brain Cancer; Skull Base Tumor

Summary: this is a prospective, observational clinical trial investigating the morphological and volumetric changes in the brain following cranial radiation therapy in pediatric patients with brain or skull base tumors.

brain injury is a known complication of cranial rt, but little is known about the factors that predispose patients to such injury. the brain is a highly interconnected organ linked through neuronal connections, cellular migration, and vascular supply and is endowed with exquisitely radiosensitive stem cell niches responsible for neuro-regeneration. to date, the effects of brain radiation have been quantified in few brain substructures. the majority of publications on this topic have focused on regions receiving higher doses. even low dose radiation exposure, however has global implications on brain development and function, and its effects are less well studied. it is increasingly recognized that radiation damage to one brain region can potentially affect brain development more broadly. this has important implications on rt planning and the potential for understanding its long-term effects. in this protocol, the investigators aim to measure serum inflammatory cytokine levels and other molecular biomarkers at baseline and post-exposure in an exploratory manner to investigate potential associations with the risk of developing volumetric changes in the brain and radiation-induced toxicities. this study will observe sixty (60) patients under the age of 21 with brain or base of skull tumor. the study team will observe the effect of radiation therapy per the study protocol versus standard of care.

Eligibility criteria:
inclusion criteria: * patient (parent) must give study-specific informed consent on an irb-approved consent prior to any research related procedures or study treatment. written assent will be obtained as per institutional guidelines. * patients (age equal to or less than 35 years old) that are planned to receive photon or proton rt to the brain according to standard of care are eligible to participate. * patients that are planned to receive fractionated rt at 1.2-2.0 gy rbe dose per fraction per standard of care are eligible to participate. if patients are planned to receive an alternative dose/fractionation regimen, then they should be treated according to standard of care and should not be enrolled. * zubrod/eastern cooperative oncology group (ecog) performance status ≤1 exclusion criteria: * patient cannot undergo mri without contrast as per standard of care * patient and family do not speak english or spanish * patient receiving treatment with non-curative intent * patients with an expected 3-year overall survival less than 50%

Keywords: brain pediatrics brain cancer pediatrics skull
determinants of repeated spontaneous miscarriages and unexplained fetal deaths

Conditions: Repeated Spontaneous Miscarriages; Fetal Deaths in Utero

Summary: the defi-1 study recruited 625 women witnesses and 299 of their spouses. with regard to case couples, 271 cases were recruited from the spontaneous repeated miscarriages (srm) subgroup (≥3 spontaneous miscarriage (sm) from trimester 1 of pregnancy) and 93 from the unexplained fetal death in utero (fdiu) subgroup from trimesters 2 and 3 of pregnancy. the main objective of the defi 2 study is to increase the number of case-pairs in these 2 particular subgroups to replicate the results of the genetic determinants highlighted from cases and controls with extreme phenotypes and obtain a sufficient number of women with fdius to identify specific determinants.

the spontaneous repeated miscarriages (srm) affect one to two fertile couples on 100, a fetal death in utero (fdiu) complicates the evolution of a pregnancy on 200. the srm remain unexplained in 50% of the cases although a beam indirect arguments sometimes encourage to evoke a prothrombotic process and / or endothelial dysfunction, immunological disorders, an alteration of the ovarian reserve, and possibly the impact of genetic determinants. regarding srm, in the absence of a fetal, funicular cause or obvious preeclampsia, very diverse mechanisms are evoked depending on the placental histology (vasculoplacental, inflammatory, intervillitis, immunological, etc.). thus, while these mechanisms remain for some to be demonstrated and are probably not unequivocal, clinicians are faced with a pressing request for therapeutic intervention on the part of patients. this is why, after having studied in defi-1 the 2 main constitutional thrombophilia in the 2 members of the couple, the procoagulant circulating microparticles and the generation of thrombin in the mother on the one hand, the modalities of inactivation of an x in the mother, on the other hand, a further investigation in subgroups of particular cases would be appropriate.

Eligibility criteria:
inclusion criteria: * couples whose wife is over 18 and under 40 inclusive, * couples having undergone at least 3 unexplained sm in the first trimester or an fdiu in the trimesters 2 and 3 of pregnancy (excluding funicular and fetal causes and proven preeclampsia) * the man must be over 18 years old. * each member of the couple must consent to the investigation. * subjects benefiting from a social security scheme. exclusion criteria: * couples where the woman is under 18 or over 40, * couples whose man is under 18, * identified cause of srm or fdiu * inability to consent for one of the members of the couple, * refusal to participate for one of the members of the couple. * treatment with anticoagulants or anti-aggregating platelet for women. * person under legal protection * subjects not benefiting from a social security scheme * refusal to participate
epstein-barr virus and cancer risks

Conditions: Cancer

Summary: the goal of this prospective cohort study is to investigate the associations between epstein-barr virus (ebv) antibody levels and the risk of overall and site-specific cancer types in southern china. the main questions it aims to answer are: question 1: in addition to the established ebv-associated cancer types, such as lymphomas, nasopharyngeal carcinoma, and stomach cancer, whether ebv is associated with other cancer types? question 2: what's the cancer burden attributed to ebv in southern china?

growing molecular evidence suggests the involvement of ebv in various cancers, however, comprehensive epidemiological evidence is still lacking. in this study, researchers conducted a population-based prospective cohort study to investigate the associations between ebv antibodies and the risk of overall and site-specific cancer types in southern china. all the participants underwent ebv antibody tests at enrollment and were subsequently followed up annually for cancer incidence, vital status, and immigration status. the primary objective of this study was to provide prospective evidence for the role of ebv in multiple cancers, shedding light on the etiology of a broad range of common ebv-associated cancers.

Eligibility criteria:
inclusion criteria: * subject residents in zhongshan or wuzhou city; * subject has no medical record of prevalent cancer; * subject has psychical condition and well consciousness, and willingness to accept and cooperate with the study\&#39;s follow-up procedures. exclusion criteria: * subject has heavy cardiovascular, liver, or kidney disease; * subject has prevalent cancer.

Keywords: ebv prospective study cancer
efficacy and safety of ravidasvir in combination with danoprevir/r and ribavirin(rbv) in treatment-naive, non-cirrhotic, chronic hepatitis c virus genotype1 infected subjects.

Conditions: HCV

Summary: the purpose of this study is to assess the efficacy and safety of ravidasvir in combination with danoprevir/r and ribavirin(rbv) by sustain virologic response 12 (svr12), in treatment-naive, non-cirrhotic, chronic hepatitis c genotype 1 infected patients.


Eligibility criteria:
inclusion criteria: * infection with chronic hepatitis c genotype 1confirmed at screening; * anti-hcv positive； * hcv rna ≥1 × 10000iu / ml; * not treated with interferon and / or any other direct-acting antiviral (daa) drug; * non-cirrhotic; * voluntarily sign informed consent. exclusion criteria: * hcv genotypes 2 to 7 or undetectable hcv genotype or mixed hcv genotype; * fibroscan detection result \> 12.9kpa or histopathological examination result of patients is with cirrhosis; * past or existing evidence of the presence of non-hcv-induced chronic liver disease; * previous history of hepatocellular carcinoma, or suspected hepatocellular carcinoma found prior to screening, or suspected abdominal hepatoblastoma at screening or afp\>100ng/ml; * anti-hav (igm) 、hbsag 、anti-hev (igm) or anti-hiv is positive; * bmi\<18 or≥30 kg/m2; * anc\ 1.5；alt or ast≥5\*uln；tbil≥2\*uln（dbil≥ 35%tbil）；cr≥1.5\*uln; * others as specified in detailed protocol.

Keywords: hcv ravidasvir svr12